Background {#Sec1}
==========

Low molecular weight heparins (LMWH) are extensively used as anticoagulation for primary and secondary prophylaxis against thrombosis, particularly in patients with malignancy. There are several known dermatological side-effects of LMWH, including injection site hematoma and skin necrosis, eczematous dermatitis, and the lesser known bullous hemorrhage dermatosis (BHD). The latter was first described in 2004 by Dyson et al. \[[@CR1]\]. It typically presents as intra-epidermal lesions found mainly on the extremities and torso, with a black appearance. The lesions occur at sites distant from injection, suggesting a systemic mechanism. There have been several small case series on BHD, but none have captured a complete review of reported cases. The frequent use of LMWH warrants systematic review of this side-effect so clinicians recognize its characteristics and know how to intervene. We sought to describe a case of BHD at our institution and provide a complete summary of the existing English and Spanish literature.

Methods {#Sec2}
=======

We performed a literature search of Pubmed, Scopus, Ovid Embase and Ovid Medline. The keywords for the search were "bullous" "hemorrhagic" and "dermatitis". Of the initial 213 search results, 51 were found to be duplicates. The remaining 162 were reviewed by title and abstract. Of these, 33 were deemed relevant to BHD, and the entire article was reviewed. The majority of the excluded search results either did not include anticoagulant use or were relevant to dermatologic diseases other than BHD.

Results {#Sec3}
=======

Case presentation {#Sec4}
-----------------

Our patient is a 62-year-old male with multiple comorbidities including morbid obesity, coronary artery disease, lipodermatosclerosis of the lower extremities, chronic peripheral venous insufficiency, and prostate cancer (Gleason 4+5) on long-term androgen deprivation therapy. He was previously treated with docetaxel for pelvic lymph node metastases. The patient also had a small renal tumor for which he was followed with imaging. He had a distant history of varicose vein ligation. While undergoing surveillance imaging to evaluate for spread of his prostate cancer, an incidental pulmonary embolism was discovered. He was started on enoxaparin 120 mg by subcutaneous injection twice daily. Within several days the patient noticed several small black blisters on his hands that resolved spontaneously. These were not reported by the patient or observed by any practitioner during routine clinic visits. The timeline of development of hemorrhagic skin lesions of this patient is outlined in Fig. [1](#Fig1){ref-type="fig"}. Four months after starting anticoagulation with enoxaparin, he presented with several large hemorrhagic bullae on his calves (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). His coagulation values and his platelet count were within normal range. The diagnosis of bullous hemorrhagic dermatosis (BHD) was made by visual inspection. Therefore, no biopsy was performed. Enoxaparin was discontinued and apixaban was started as alternative anticoagulation. The lesions healed in 3 weeks with intensive outpatient wound care and have not recurred to date while on apixaban.Fig. 1Timeline of clinical events Fig. 2Left anterior lower extremity bulla Fig. 3Right posterior lower extremity bulla

Review of reported cases in the English and Spanish literature {#Sec5}
--------------------------------------------------------------

We describe 90 cases of BHD discovered in our literature search, in addition to our local case (Table [1](#Tab1){ref-type="table"}) \[[@CR1]--[@CR33]\]. Cases were reported from the US, Spain, France, Turkey, Austria, and Australia. Spain appeared to have the most representation in the literature. Serious comorbidities were common, such as carcinomas of lung, prostate, and ovary, lymphoma, and cardiomyopathy. The cases demonstrate a variety of indications and dosages for anticoagulation (not shown in table). Indications for weight-based, full dose anticoagulation included atrial fibrillation, venous thromboembolism, aortic stenosis, left ventricular thrombus, and acute coronary syndromes. Patients also received primary prophylactic dosing for hospitalized patients. Before their incident BHD, most patients had not been exposed to anticoagulation. A minority of patients received warfarin before diagnosis; none received direct oral anticoagulants (DOAC). Most patients had normal PT and PTT values before initiation of anticoagulation, and were in therapeutic range while on treatment (not shown). A minority of patients were on aspirin at the time of diagnosis. Most patients had a punch skin biopsy, and all were negative for signs of vasculitis. Intraepidermal hemorrhage was the common pathological finding. The eruption was mainly located on the extremities, and less frequently on the torso.Table 1Summary of cases (n = 91), part I, part II, part IIIReferencesAgeGenderAgentDays to lesionLocationInterventionDays to resolutionPart I \[[@CR1]\]62FEnoxaparinUnknownButtockAC changed to warfarin14 \[[@CR1]\]32MEnoxaparin14Lower extremitiesAC discontinued7 \[[@CR2]\]75MDalteparin5Hands and groinAC changed to coumadin, died of IC 14 days laterDeath \[[@CR2]\]82FTinzaparin6ExtremitiesAC discontinued10 \[[@CR2]\]64MHeparin Calcium21Forearms and anklesAC continuedYes, unknown \[[@CR3]\]72FEnoxaparin2Abdomen and upper extremitiesAC changed to oral after planned intervention14 \[[@CR3]\]57MEnoxaparin3Abdomen and upper and lower extremitiesUnknownUnknown \[[@CR4]\]88MEnoxaparin then warfarin14Left arm and ankleAC discontinued14 \[[@CR5]\]51UnknownEnoxaparin then tinzaparin2Upper and lower extremities, abdomenAC discontinuedUnknown \[[@CR6]\]86MEnoxaparin1Trunk, extremitiesAC continued30 \[[@CR6]\]87MEnoxaparin5Limbs and handsAC continued21 \[[@CR6]\]73FBemiparin then Enoxaparin1Lower extremitiesChanged to rivaroxaban, died 10 days laterDeath \[[@CR6]\]72MBemiparin30Trunk, legsAC continued21 \[[@CR6]\]82MEnoxaparin3ArmsAC continued21 \[[@CR7]\]68MEnoxaparin8Hand, neck, and faceUnknown14 \[[@CR7]\]78MEnoxaparin10Knees and forearmAC continued14 \[[@CR8]\]85MEnoxaparin3Torso and legsAC discontinuedUnknown \[[@CR9]\]73MEnoxaparin14Upper extremitiesAC continued14 \[[@CR10]\]77MEnoxaparin3Trunk, right handAC discontinued2 \[[@CR10]\]94MTinzaparin15Trunk, limbsAC discontinued10 \[[@CR11]\]59FEnoxaparin30Dorsal handAC continued4 \[[@CR12]\]68MEnoxaparin1Feet, leg, neck, hands dorsumAC discontinuedUnknown \[[@CR12]\]77MEnoxaparin8Dorsum of feet, dorsum of handsAC discontinuedUnknown \[[@CR13]\]88FEnoxaparin5LegsAC changed to warfarinUnknown \[[@CR14]\]87FEnoxaparin10Knees, forearms, elbowsUnknown14 \[[@CR15]\]71MEnoxaparin2AbdomenAC discontinued7 \[[@CR16]\]90MEnoxaparin8Left arm and ankleAC continued14 \[[@CR17]\]73MEnoxaparin6Left palmAC continued14Part II \[[@CR18]\]63MEnoxaparin12Lower extremitiesAC continued3 \[[@CR18]\]74MEnoxaparin13Lower extremitiesAC continued3 \[[@CR19]\]83MWarfarin + UFH5Arms, flank, thighsHeparin discontinuedYes, unknown \[[@CR20]\]77MEnoxaparin5UnknownChanged to dabigatran14 \[[@CR21]\]82FWarfarin10ExtremitiesChanged to enoxaparinWorsening lesions, resolved after all AC stopped \[[@CR22]\]90MEnoxaparin8Ankle and wristAC continued14 \[[@CR22]\]65MEnoxaparin9Lower and upper extremitiesChanged to tinzaparin as lesions persisted for 6 weeks on enoxaparin14 \[[@CR22]\]64MEnoxaparin7Lower and upper extremitiesAC continued21 \[[@CR22]\]89MEnoxaparin10Lower and upper extremities scalp and backAC discontinued21 \[[@CR22]\]74MEnoxaparin20Hand and legAC discontinued14 \[[@CR23]\]71MEnoxaparin14Forearms, hands, kneesAC continuedPersisting lesions for 6 months, resolved after AC stopped \[[@CR24]\]64MEnoxaparin5Arms and handsDose reduced14 \[[@CR25]\]74MEnoxaparin5Upper and lower extremities, abdomenAC discontinued7 \[[@CR26]\]52MEnoxaparin7Lower and upper extremitiesAC continued3 \[[@CR27]\]77FEnoxaparin15LimbsAC continued14 \[[@CR28]\]77FEnoxaparin5Hands and shinsAC continued, fatal ICH 4 weeks later12 \[[@CR29]\]72MEnoxaparin7Arm and legsAC changed to UFH7 \[[@CR30]\]59FEnoxaparin270LegsAC changed to fondaparinux then rivaroxabanUnknown \[[@CR30]\]51FFondaparinuxUnknownLegsAC changed to rivaroxaban3 \[[@CR31]\]75FEnoxaparin3Arms, hands, feetAC held, lesions resolved, AC restarted and lesions re-appeared, improved with steroids, patient had past history of bullous pemphigoid28Part III \[[@CR32]\]60MUFH5Limbs and trunkAC continuedUnknown \[[@CR32]\]68FUFH then enoxaparin7Abdomen, hands, feetAC changed to rivaroxaban21 \[[@CR32]\]64MEnoxaparin, warfarin9Lower and upper extremitiesAC discontinued30 \[[@CR32]\]38FUFH7Chest and ankleAC discontinued7 \[[@CR32]\]72FEnoxaparin2ForearmAC discontinued2 Ref. \[[@CR33]\];\
Case series of 37 cases, 1985--201577.4M 20\
F 17LMWH\
Fondaparinux\
Sodic heparin\
Calcic heparin8.8Limbs and trunkAC discontinued in 34 cases\
AC continued in 1 case\
Unknown in 2 casesUnknown Case currently reported62MEnoxaparin7Calf and handsAC continued with worsening lesions, after 4 months changed to apixaban21 after change to apixaban*AC* anticoagulation, *F* female, *ICH* intracranial hemorrhage, *LMWH* low molecular weight heparin, *M* male, *UFH* unfractionated heparin

Summary statistics were extracted based on our review of the literature (Table [2](#Tab2){ref-type="table"}). The average case age was 72 ± 12, and there was a 1.9:1 male to female ratio. Enoxaparin was the most frequent culprit anticoagulant (66%), followed by fondaparinux (12%). On average, lesions appeared after 7 days of treatment (7.0 ± 6.4), and resolved after 2 weeks of discontinuation of anticoagulation (13.0 ± 7.4). Most cases of bullous lesions (67.9%) were reported on the extremities only, followed by torso and extremities (26.4% of cases). Lesions on the head and neck were rare (5.5%). Management consisted of discontinuation of culprit anticoagulant (57% of cases), continuation (23.1%), or treatment change or dose reduction (14.3%). There was no difference in time to resolution between patients who continued the culprit anticoagulant or changed to a different anticoagulant, and those who discontinued anticoagulation altogether (13.9 days vs. 12.1, p = 0.49).Table 2Descriptive statistics from 91 cases of BHDDescriptorStatisticAge in years, average ± SD72 ± 12Sex  % (n) Male64% (58) Female36% (33)Anticoagulation drug,  % (n) Enoxaparin only66% (61) Fondaparinux12% (11) UFH only9% (8) Bridging heparin + enoxaparin6.5% (6) Other LMWH or ULMWH5.4% (5) Coumadin only1% (1)Time to lesion onset, days, mean ± SD7.0 ± 6.4Location  % (n) Extremities only67.9% (36) Extremities +torso26.4% (14) Face, neck, head included5.7% (3)Management  % (n) Discontinued57% (52) Continued23.1% (21) Treatment changed or dose reduced14.3% (13) Unknown5.5% (5)Time to resolution, days, mean ± SD13.0 ± 7.4 If continued any AC13.9 ± 7.8 Discontinued AC12.1 ± 7.9

Discussion {#Sec6}
==========

The review of BHD presented here is the largest collection of cases compiled from the English and Spanish literature to our knowledge. BHD has been documented in medical reports, but appears under-recognized in the clinical practice. We also presented a case from our own institution.

BHD is a non-immune dermatological eruption related to anticoagulation given for either primary or secondary prophylaxis. Enoxaparin is the most common culprit anticoagulant, followed by fondaparinux. Lesions are distant from the site of injection. Clinical or pathological signs of inflammation are absent. The extremities are the primary sites of eruptions in many cases. BHD caused by DOACs is not specified to date from several examples of large clinical trials for VTE treatment \[[@CR34]--[@CR36]\]. No patients in our series received DOACs before diagnosis.

Our case is unusual for the delay of 4 months in the appearance of BHD consisting of very large lesions in the lower extremities. Most lesions will appear within 7 days of the first anticoagulation administration. Their appearance is usually of small, dark bullae, rather than large hemorrhagic bullae. Lesions are not painful. In retrospect, our patient did recall having small blisters on his hands that occurred within days of starting enoxaparin. However, he did not report these small skin lesions as they resolved spontaneously. He sought medical attention after developing large dark bullae on both calves.

From our viewpoint, if characteristics of BHD are present as outlined above and in Table [2](#Tab2){ref-type="table"}, historical and clinical evaluation may be satisfactory to make the diagnosis. A biopsy should be performed if the diagnosis is in doubt. In our patient's case, prostate cancer treatment with androgen deprivation is an unlikely cause. While injection-site granuloma and serum sickness have been reported with depot leuprolide acetate \[[@CR37]--[@CR39]\], to our knowledge, there are no reports of eruptions similar to BHD with leuprolide.

After the appearance of BHD, maintaining anticoagulation with a LMWH may increase a patient's risk of recurrent bullae \[[@CR21], [@CR22], [@CR31]\]. Nevertheless, 21 patients in our review continued on anticoagulation with a LMWH without report of recurrence. It is suspected that higher doses of LMWH may increase time to resolution of BHD \[[@CR22]\]. No treatment is needed beyond managing anticoagulation and skin care as in this case. Discontinuing treatment may not be necessary if lesions are small.

BHD is sometimes associated with eczematous reaction at sight of injection that may suggest a type IV hypersensitivity reaction \[[@CR32]\]. The propensity for developing lesions on the extremities in older patients also posits local trauma combined with epidermal-dermal fragility as an underlying mechanism \[[@CR10]\]. There is no apparent association of BHD with any comorbidity. While there is no evidence indicating a higher risk for BHD with venous insufficiency, one could speculate that the pre-existing chronic leg edema in our patient facilitated the large size of the bullous lesions.

Of the 91 cases presented, there were four cases that had bleeding complications, two with fatal intracranial hemorrhage \[[@CR2], [@CR28]\]. Available coagulation tests were normal in these patients at the onset of anticoagulation. In Perrinaud et al. \[[@CR2]\], the bleeding event occurred with a supratherapeutic INR. In Yurekli et al. \[[@CR28]\], the fatal event occurred after continuing enoxaparin, but the bullous lesions had resolved at the time of death. The documented rate of intracranial hemorrhage in the CLOT trial while using LMWH for a 6-month study period was one out of 338 \[[@CR40]\].

Conclusion {#Sec7}
==========

Hemorrhagic bullous dermatosis secondary to LMWH usage has been reported in the literature but is under-recognized. In this case report the diagnosis was not made until the patient presented with large hemorrhagic bullae after 4 months of LMWH. Biopsy may not be required if the clinical characteristics of BHD are present. The anticoagulation of choice may be continued if lesions are small and are resolving. Risk evaluation for bleeding may proceed along standard guidelines. This case series also highlights a need for clinical reporting of BHD when using DOACs.
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